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Von Willebrand factor is a multimeric glycoprotein that is crucial for physiologic platelet adhesion and aggregation at high shear rates of blood flow, and the largest von Willebrand factor multimers are the most adhesive. The hemostatic power of von Willebrand factor is regulated by a specific cleaving metalloprotease named ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13). Since 1998, the link between TTP, von Willebrand factor, and ADAMTS13 has been elucidated [2] [3] [4] [5] : a severe functional deficiency of ADAMTS13 (due mainly to anti-ADAMTS13 autoantibodies and very rarely to ADAMTS13 gene mutations) causes the accumulation of platelethyperadhesive, ultralarge von Willebrand factor multimers in the blood, spontaneously inducing the formation of microthrombi in the microvasculature.
The discovery of ADAMTS13 led to both the solution to the enigma of the pathophysiology of TTP and the understanding of the basis for the efficacy of daily plasma exchange, which has been used empirically since the 1990s. Before plasma exchange, TTP was often fatal. 6 It is now clear that therapeutic plasma is a source of ADAMTS13 that acts as replacement therapy and that the exchange process removes the anti-ADAMTS13 autoantibodies (Fig. 1) .
Today, plasma exchange remains the frontline therapy in patients with TTP. A possible alternative replacement therapy for the future is recombinant ADAMTS13, which has not yet been tested in humans. In addition, to target anti-ADAMTS13 autoantibodies, several approaches to immune-complex inhibition have been used: glucocorticoids (frontline therapy with plasma exchange), vincristine and cyclophosphamide (rarely used), splenectomy (salvage therapy), and for about the past 10 years, rituximab (a monoclonal antibody targeting the CD20 antigen of B lymphocytes) (Fig. 1 ). The efficacy of these immunomodulating treatments has not been proved by means of randomized, prospective trials, but several case series have shown that rituximab is very promising in the treatment of refractory TTP or a relapse of TTP. 7 Other immunologic approaches with the use of cyclosporine (an inhibitor of T-cell activation), eculizumab (an anti-C5 monoclonal antibody), or bortezomib (a proteasome inhibitor) were also used anecdotally to treat TTP 8 ( Fig. 1 ). Despite these major therapeutic advances, the global mortality associated with TTP is about 15%. In the patients who die, the vicious cycle of von Willebrand factor-dependent thrombi formation is most likely not disrupted fast enough by therapies targeting ADAMTS13 and its specific autoantibodies. Thus, a more direct and rapidly acting treatment approach would be to inhibit the binding of von Willebrand factor to platelets, either by reducing the size of von Willebrand factor multimers with N-acetylcysteine 8 or, more powerfully, by blocking the binding of von Willebrand factor to platelets.
Caplacizumab is a single-variable-domain immunoglobulin (Nanobody) directed to the A1 region of von Willebrand factor, which specifically inhibits its interaction with platelet glyco- 
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protein Ib under high shear conditions. Caplacizumab showed its safety and efficacy in preventing thrombosis in a baboon model of acquired TTP. 9 In this issue of the Journal, Peyvandi et al. 10 present the TITAN study, an international, multicenter, phase 2, randomized, placebo-controlled study of caplacizumab that was designed to assess its efficacy and safety (as an adjunct to plasma exchange) in patients with acquired TTP. Seventy-five patients were enrolled. As compared with placebo, caplacizumab showed a short-term efficacy by reducing both the time to platelet count normalization and the early exacerbation rate, but it did not have an effect on the risk of relapse of TTP. Caplacizumab was associated with an increased tendency toward bleeding as compared with placebo, a potential outcome of blocking the interaction of von Willebrand factor with platelets.
It is interesting to speculate that effective TTP treatment will involve a combination of interventions that target different aspects of the pathophysiology. ADAMTS13 replacement with either normal plasma or perhaps recombinant product would restore processing of von Willebrand factor multimers to the appropriate size. Formation of new microthrombi can be blocked by interfering with the binding of von Willebrand factor to platelets, as shown by the efficacy of caplacizumab. The autoantibody to ADAMTS13 can be inhibited by selective suppression of the B cells that produce the antibody -for example, with rituximab or other anti-B-cell antibodies. A remaining goal is the disaggregation of platelet-rich thrombi. Many questions remain with regard to the optimal timing and sequencing of these therapeutic options in the management of TTP, not only in the curative treatment of patients in acute phases but also in the prevention of relapses.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org. Therapeutic options indicated in bold (plasma exchange, rituximab, and glucocorticoids) are those approved and commonly used in 2016. Splenectomy is in italics because it is the only surgical procedure listed and is rarely used. The asterisk indicates that recombinant ADAMTS13 has not been tested in humans yet. Other drugs are either historical therapies (vincristine, cyclophosphamide, and cyclosporine) or emerging therapies (caplacizumab, N-acetylcysteine, eculizumab, and bortezomib). 
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